Advocacy intelligence hub — real-time data for patient organizations
Amtagvi: FDA approved
treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Amtagvi
Iovance Biotherapeutics, Inc.
Amtagvi
(lifileucel)Orphan drugIovance Biotherapeutics, Inc.
12.1 Mechanism of Action The specific mechanism of action of AMTAGVI (lifileucel) is unknown.
Browse all Primary melanoma of the central nervous system news →
Jing Li
M.D. Anderson Cancer Center
Jordi Rodon Ahnert, APRN
M.D. Anderson Cancer Center
📍 BRUNSWICK, GA
Roxana S. Dronca, MD
Mayo Clinic
📍 Jacksonville, Florida
Shivaani Kummar, MD
NCI - Medical Oncology Branch
📍 PORTLAND, OR
Lee R Morgan, MD, PhD
DEKK-TEC, Inc.
Mohammad K Khan, MD, PhD
Emory University Hospital/Winship Cancer Institute
View all Primary melanoma of the central nervous system specialists →